Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141)
An Open Label, Randomized Phase 3 Clinical Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Platinum-refractory Squamous Cell Carcinoma of the Head and Neck (SCCHN)
研究概览
研究类型
注册 (实际的)
阶段
- 第三阶段
联系人和位置
学习地点
-
-
British Columbia
-
Vancouver、British Columbia、加拿大、V5Z 4E6
- Local Institution - 0038
-
-
Ontario
-
London、Ontario、加拿大、N6A 4L6
- Local Institution - 0045
-
-
-
-
-
Tainan、台湾、704
- Local Institution - 0065
-
Taipei、台湾、100
- Local Institution - 0064
-
-
-
-
-
Seoul、大韩民国、135-710
- Local Institution - 0067
-
Seoul、大韩民国、137-701
- Local Institution - 0066
-
-
-
-
-
Sao Paulo、巴西、01321-001
- Local Institution - 0055
-
-
RIO Grande DO SUL
-
Ijui、RIO Grande DO SUL、巴西、98700-000
- Local Institution - 0054
-
-
Rio Grande Do Sul
-
Porto Alegre、Rio Grande Do Sul、巴西、90610-000
- Local Institution
-
-
-
-
-
Berlin、德国、12200
- Local Institution - 0047
-
Bonn、德国、53127
- Local Institution - 0049
-
Essen、德国、45122
- Local Institution - 0048
-
Hamburg、德国、20246
- Local Institution - 0052
-
Hannover、德国、30625
- Local Institution - 0046
-
Wuerzburg、德国、97070
- Local Institution - 0050
-
-
-
-
-
Milano、意大利、20142
- Local Institution
-
Napoli、意大利、80131
- Local Institution
-
Padova、意大利、35128
- Local Institution
-
-
FC
-
Meldola、FC、意大利、47014
- Ist.Scient. Romagnolo Per Lo Studio E Cura Tumori
-
-
MI
-
Milano、MI、意大利、20133
- Local Institution
-
-
TO
-
Torino、TO、意大利、10126
- Local Institution
-
-
-
-
-
Akashi, Hyogo、日本、673-8558
- Local Institution - 0057
-
Tokyo、日本、135-8550
- Local Institution - 0061
-
-
Aichi
-
Nagoya、Aichi、日本、4648681
- Local Institution - 0056
-
-
Chiba
-
Kashiwa、Chiba、日本、2778577
- Local Institution - 0060
-
-
Hokkaido
-
Sapporo-shi、Hokkaido、日本、0608648
- Local Institution - 0062
-
-
Hyogo
-
Kobe-shi、Hyogo、日本、650-0017
- Local Institution - 0058
-
-
Osaka
-
Takatsuki、Osaka、日本、5698686
- Local Institution - 0063
-
-
Shizuoka
-
Sunto-gun、Shizuoka、日本、4118777
- Local Institution - 0059
-
-
-
-
-
Lyon Cedex 08、法国、69373
- Local Institution
-
Nice Cedex 2、法国、06189
- Local Institution
-
Villejuif Cedex、法国、94805
- Local Institution
-
-
-
-
-
Zuerich、瑞士、8091
- Local Institution - 0051
-
-
-
-
California
-
Stanford、California、美国、94305
- Stanford University Medical Center
-
-
Florida
-
Tampa、Florida、美国、33612
- H. Lee Moffitt Cancer Center
-
-
Georgia
-
Atlanta、Georgia、美国、30322
- Local Institution - 0001
-
-
Illinois
-
Chicago、Illinois、美国、60637
- Local Institution - 0002
-
-
Louisiana
-
Metairie、Louisiana、美国、70006
- Local Institution - 0004
-
-
Massachusetts
-
Boston、Massachusetts、美国、02215
- Beth Israel Deaconess Medical Center
-
Boston、Massachusetts、美国、02215
- Dana-Farber Cancer Institute
-
-
Michigan
-
Ann Arbor、Michigan、美国、48109
- University of Michigan
-
-
North Carolina
-
Durham、North Carolina、美国、27710
- DUMC
-
-
Ohio
-
Columbus、Ohio、美国、43210
- Local Institution - 0012
-
-
Pennsylvania
-
Pittsburgh、Pennsylvania、美国、15213
- Local Institution - 0007
-
-
Tennessee
-
Nashville、Tennessee、美国、37232
- Vanderbilt Cancer Clinic
-
-
Texas
-
Hoston、Texas、美国、77030
- Univ Of Tx. Md Anderson
-
-
Utah
-
Salt Lake City、Utah、美国、84112
- Huntsman Cancer Institute
-
-
Wisconsin
-
Milwaukee、Wisconsin、美国、53226
- Local Institution - 0031
-
-
-
-
-
Surrey、英国、SM2 5PT
- Local Institution
-
-
Greater London
-
London、Greater London、英国、SW3 6JJ
- Local Institution
-
-
Greater Manchester
-
Manchester、Greater Manchester、英国、M20 4BX
- Local Institution
-
-
Hampshire
-
Southampton、Hampshire、英国、SO16 6YD
- Local Institution
-
-
Merseyside
-
Wirral、Merseyside、英国、CH63 4JY
- Local Institution
-
-
-
-
-
Amsterdam、荷兰、1081 HV
- Local Institution
-
Groningen、荷兰、9713 AP
- Local Institution
-
Leiden、荷兰、2333 ZA
- Local Institution
-
-
-
-
-
Barcelona、西班牙、08035
- Local Institution - 0032
-
Barcelona、西班牙、08036
- Local Institution - 0035
-
Madrid、西班牙、28041
- Local Institution - 0034
-
Valencia、西班牙、46010
- Local Institution - 0033
-
-
-
-
-
Cordoba、阿根廷、5000
- Local Institution - 0014
-
-
Buenos Aires
-
Berazategui、Buenos Aires、阿根廷、1880
- Local Institution - 0015
-
-
Tucuman
-
San Miguel De Tucuman、Tucuman、阿根廷、4000
- Local Institution - 0013
-
-
-
-
-
Hong Kong、香港
- Local Institution
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com
Inclusion Criteria:
- Men and women ≥ 18 years of age with an Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1
- Histologically confirmed recurrent or metastatic SCCHN (oral cavity, pharynx, larynx), stage III/IV and not amenable to local therapy with curative intent (surgery or radiation therapy with or without chemotherapy)
- Tumor progression or recurrence within 6 months of last dose of platinum therapy in the adjuvant (ie with radiation after surgery), primary (ie, with radiation), recurrent, or metastatic setting
- Measurable disease by Computed tomography (CT) or Magnetic resonance imaging (MRI) per Response Evaluation Criteria In Solid Tumors (RECIST 1.1) criteria
Exclusion Criteria:
- Active brain metastases or leptomeningeal metastases are not allowed
- Histologically confirmed recurrent or metastatic carcinoma of the nasopharynx, squamous cell carcinoma of unknown primary, and salivary gland or non-squamous histologies (eg: mucosal melanoma) are not allowed
- Subjects with active, known or suspected autoimmune disease
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
---|---|
实验性的:Arm A: Nivolumab
Nivolumab 3mg/kg intravenous (IV) Solution for Injection every 2 weeks until disease progression
|
其他名称:
|
有源比较器:Arm B: Cetuximab/Methotrexate/Docetaxel
Cetuximab intravenous (IV) Solution for Injection 400 mg/m2 (first dose) then 250 mg/m2 weekly until disease progression OR Methotrexate intravenous (IV) Solution for Injection 40 or 60 mg/m2 weekly until disease progression OR Docetaxel intravenous (IV) Solution for Injection 30 or 40 mg/m2 weekly until disease progression |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
---|---|---|
Overall Survival (OS)
大体时间:From date of randomization to date of death (Up to approximately 18 months)
|
OS was defined as the time from randomization to the date of death from any cause.
Participants were censored at the date they were last known to be alive and at the date of randomization if they were randomized but had no follow-up.
Median OS time was calculated using Kaplan-Meier (KM) method.
|
From date of randomization to date of death (Up to approximately 18 months)
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
---|---|---|
Investigator-Assessed Progression-Free Survival (PFS)
大体时间:From date of randomization to date of disease progression or death, whichever occurs first (Up to approximately 87 months)
|
PFS was defined as the time between the date of randomization and the first date of documented progression, as determined by the investigator (as per Response Evaluation Criteria In Solid Tumors (RECIST1.1)), or death due to any cause, whichever occurs first. Progressive Disease: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. The sum must demonstrate an absolute increase of at least 5mm. Participants who:
|
From date of randomization to date of disease progression or death, whichever occurs first (Up to approximately 87 months)
|
Investigator-Assessed Objective Response Rate (ORR)
大体时间:From date of randomization to date of disease progression or study drug is discontinued, whichever occurs first (Up to approximately 87 months)
|
ORR was defined as the percentage of randomized participants who achieved a best response of complete response (CR) or partial response (PR) using the RECIST1.1 criteria as per investigator assessment.
Complete Response (CR): Disappearance of all target lesions.
Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions.
|
From date of randomization to date of disease progression or study drug is discontinued, whichever occurs first (Up to approximately 87 months)
|
合作者和调查者
出版物和有用的链接
一般刊物
- Yen CJ, Kiyota N, Hanai N, Takahashi S, Yokota T, Iwae S, Shimizu Y, Hong RL, Goto M, Kang JH, Li WSK, Ferris RL, Gillison M, Endo T, Jayaprakash V, Tahara M. Two-year follow-up of a randomized phase III clinical trial of nivolumab vs. the investigator's choice of therapy in the Asian population for recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141). Head Neck. 2020 Oct;42(10):2852-2862. doi: 10.1002/hed.26331. Epub 2020 Jun 24.
- Saba NF, Blumenschein G Jr, Guigay J, Licitra L, Fayette J, Harrington KJ, Kiyota N, Gillison ML, Ferris RL, Jayaprakash V, Li L, Brossart P. Nivolumab versus investigator's choice in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: Efficacy and safety in CheckMate 141 by age. Oral Oncol. 2019 Sep;96:7-14. doi: 10.1016/j.oraloncology.2019.06.017. Epub 2019 Jul 3.
- Cocks K, Contente M, Simpson S, DeRosa M, Taylor FC, Shaw JW. A Q-TWiST Analysis Comparing Nivolumab and Therapy of Investigator's Choice in Patients with Recurrent/Metastatic Platinum-Refractory Squamous Cell Carcinoma of the Head and Neck. Pharmacoeconomics. 2019 Aug;37(8):1041-1047. doi: 10.1007/s40273-019-00798-1.
- Pai SI, Faivre S, Licitra L, Machiels JP, Vermorken JB, Bruzzi P, Gruenwald V, Giglio RE, Leemans CR, Seiwert TY, Soulieres D. Comparative analysis of the phase III clinical trials of anti-PD1 monotherapy in head and neck squamous cell carcinoma patients (CheckMate 141 and KEYNOTE 040). J Immunother Cancer. 2019 Apr 3;7(1):96. doi: 10.1186/s40425-019-0578-0.
- Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington KJ, Kasper S, Vokes EE, Even C, Worden F, Saba NF, Docampo LCI, Haddad R, Rordorf T, Kiyota N, Tahara M, Lynch M, Jayaprakash V, Li L, Gillison ML. Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression. Oral Oncol. 2018 Jun;81:45-51. doi: 10.1016/j.oraloncology.2018.04.008. Epub 2018 Apr 17.
- Kiyota N, Hasegawa Y, Takahashi S, Yokota T, Yen CJ, Iwae S, Shimizu Y, Hong RL, Goto M, Kang JH, Sum Kenneth Li W, Ferris RL, Gillison M, Namba Y, Monga M, Lynch M, Tahara M. A randomized, open-label, Phase III clinical trial of nivolumab vs. therapy of investigator's choice in recurrent squamous cell carcinoma of the head and neck: A subanalysis of Asian patients versus the global population in checkmate 141. Oral Oncol. 2017 Oct;73:138-146. doi: 10.1016/j.oraloncology.2017.07.023. Epub 2017 Sep 1.
- Harrington KJ, Ferris RL, Blumenschein G Jr, Colevas AD, Fayette J, Licitra L, Kasper S, Even C, Vokes EE, Worden F, Saba NF, Kiyota N, Haddad R, Tahara M, Grunwald V, Shaw JW, Monga M, Lynch M, Taylor F, DeRosa M, Morrissey L, Cocks K, Gillison ML, Guigay J. Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial. Lancet Oncol. 2017 Aug;18(8):1104-1115. doi: 10.1016/S1470-2045(17)30421-7. Epub 2017 Jun 23.
- Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington K, Kasper S, Vokes EE, Even C, Worden F, Saba NF, Iglesias Docampo LC, Haddad R, Rordorf T, Kiyota N, Tahara M, Monga M, Lynch M, Geese WJ, Kopit J, Shaw JW, Gillison ML. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med. 2016 Nov 10;375(19):1856-1867. doi: 10.1056/NEJMoa1602252. Epub 2016 Oct 8.
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- CA209-141
- 2013-003622-86 (EudraCT编号)
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.